Artificial Antigen Presentosomes for T Cell Activation

  • Yi-Geng Pang
  • Chien-Chung ChangEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 2111)


CD8+ T cells constitute an essential component of the adaptive immune system. They are activated through T cell receptor (TCR) recognizing antigenic peptides presented by MHC class I molecules expressed by antigen-presenting cells, such as dendritic cells (DCs). Harvesting a large number of activated, antigen-specific human CD8+ T cells for functional studies has been a laborious task for immunologists, largely because of the variables associated with DC preparations. Here we describe a robust, cost-effective DC-free antigen-presenting system capable of generating a large number of antigen-specific CD8+ T cells in vitro.

Key words

T cell activation Major histocompatibility complex Human leukocyte antigen Antigen presentation 



This work was supported in part by the National Science Council grant (NSC 98-2320-B-007-004-MY3) and the Ministry of Science and Technology grants (MOST 106-2320-B-007-001; MOST 107-2320-B-007-002) to C.-C. C.


  1. 1.
    Hennecke J, Wiley DC (2001) T cell receptor-MHC interactions up close. Cell 104:1–4CrossRefGoogle Scholar
  2. 2.
    Pennock ND, White JT, Cross EW, Cheney EE, Tamburini BA, Kedl RM (2013) T cell responses: naive to memory and everything in between. Adv Physiol Educ 37:273–283CrossRefGoogle Scholar
  3. 3.
    Chen L, Flies DB (2013) Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 13:221–242Google Scholar
  4. 4.
    Zhang N, Bevan MJ (2011) CD8+ T cells: foot soldiers of the immune system. Immunity 35:161–168CrossRefGoogle Scholar
  5. 5.
    Tafuro S, Meier UC, Dunbar PR, Jones EY, Layton GT, Hunter MG et al (2001) Reconstitution of antigen presentation in HLA class I-negative cancer cells with peptide-beta2m fusion molecules. Eur J Immunol 31:440–449CrossRefGoogle Scholar
  6. 6.
    Shen C, Chang CC, Zhang J, Guo W, Xia L, Meng F et al (2006) Structural and functional characterization of peptide-beta2m fused HLA-A2/MART1 (27-35) complexes. Biochem Biophys Res Commun 342:57–65CrossRefGoogle Scholar
  7. 7.
    Tsujisaki M, Sakaguchi K, Igarashi M, Richiardi P, Perosa F, Ferrone S (1988) Fine specificity and idiotype diversity of the murine anti-HLA-A2, A28 monoclonal antibodies CR11–351 and KS1. Transplantation 45:632–639 CrossRefGoogle Scholar
  8. 8.
    Lampson LA, Fisher CA, Whelan JP (1983) Striking paucity of HLA-A, B, C and beta 2-microglobulin on human neuroblastoma cell lines. J Immunol 130:2471–2478PubMedGoogle Scholar
  9. 9.
    Wang X, Liang B, Rebmann V, Lu J, Celis E, Kageshita T et al (2003) Specificity and functional characteristics of anti-HLA-A mAbs LGIII-147.4.1 and LGIII-220.6.2. Tissue Antigens 62:139–148CrossRefGoogle Scholar
  10. 10.
    Palmisano GL, Pistillo MP, Capanni P, Pera C, Nicolò G, Salvi S et al (2001) Investigation of HLA class I downregulation in breast cancer by RT-PCR. Hum Immunol 62:133–139CrossRefGoogle Scholar
  11. 11.
    Rebmann V, Pfeiffer K, Pässler M, Ferrone S, Maier S, Weiss E et al (1999) Detection of soluble HLA-G molecules in plasma and amniotic fluid. Tissue Antigens 53:14–22CrossRefGoogle Scholar
  12. 12.
    Desai SA, Wang X, Noronha EJ, Zhou Q, Rebmann V, Grosse-Wilde H et al (2000) Structural relatedness of distinct determinants recognized by monoclonal antibody TP25.99 on beta2-microglobulin-associated and beta2-microglobulin-free HLA class I heavy chains. J Immunol 165:3275–3283CrossRefGoogle Scholar
  13. 13.
    Lee SP, Tierney RJ, Thomas WA, Brooks JM, Rickinson AB (1997) Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. J Immunol 158:3325–3334PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  1. 1.Institute of Molecular and Cellular BiologyNational Tsing Hua UniversityHsinchuTaiwan

Personalised recommendations